GILD · News · 20261030N
Net Income and EPS Performance
GILEAD SCIENCES, INC. · 2026-10-30 · Importance 46 · Surprise 30 · No source text
Gilead’s third-quarter 2026 net income declined 20.4% year over year to $2.43 billion, and diluted EPS fell 20.2% to $1.94. Adjusted earnings, by contrast, increased 3.2% to $2.55 per share and exceeded the Zacks consensus estimate of $2.17. Higher product sales and lower acquisition-related R&D charges more than offset higher operating expenses and income taxes.
Key facts
- Gilead's third-quarter 2026 net income declined 20.4% year over year to $2.43 billion. source
- Gilead's third-quarter 2026 diluted EPS declined 20.2% year over year to $1.94. source
- Gilead's third-quarter 2026 adjusted earnings were $2.55 per share, up 3.2% year over year and above the Zacks Consensus Estimate of $2.17. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | -7.5% | Gilead's third-quarter 2026 net income declined 20.4% year over year to $2.43 billion. |